Atrium Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 26, 2027The maintenance fee for Nucleic Acid-Polypeptide Compositions and Uses Thereof (US 10,487,149) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Anti-Transferrin Receptor Antibodies and Uses Thereof (US 11,834,510) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Nucleic Acid-Polypeptide Compositions and Uses Thereof (US 10,550,188) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,487,149 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 10,550,188 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 10,787,519 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,800,848 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,234,290 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,351,637 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,364,302 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 11,110,180 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,364,769 | Nucleic Acid-Polypeptide Compositions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,913,800 | Anti-Transferrin Receptor Antibodies and Uses Thereof In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.